ABBVIE INC. (ABBV) Stock Price

ABBVStockS&P 500

$285.42+25.81%52W

Market Cap$504.37B

P/E119.35x

PEG Ratio0.58

Div yield4.47%

Beta0.19

ABBV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)25.84%

Price vs S&P 500 (4W)9.24%

PEG Ratio0.58

VGM Score56.94

P/E Ratio (Annual)119.35x

Indicated Dividend Yield (Annual)4.47%

P/CF (Annual)26.50x

Book Value / Share (Quarterly)$0.80

P/TBV (Annual)455.35x

Indicated Dividend (Annual)$6.92

Revenue Growth (3Y)1.75%

Cash Flow / Share (Quarterly)$10.31

Payout Ratio (TTM)189.83%

Price vs S&P 500 (YTD)12.99%

Gross Margin (TTM)72.79%

Net Profit Margin (TTM)9.80%

EPS (TTM)$3.56

10-Day Avg Trading Volume5.90M

EPS Excl Extra (TTM)$3.56

Revenue Growth (5Y)5.95%

EPS (Annual)$2.38

Dividend / Share (Annual)$6.60

ROI (Annual)6.07%

Gross Margin (Annual)71.62%

Net Profit Margin (5Y Avg)12.88%

Cash / Share (Quarterly)$3.72

P/E Basic Excl Extra (TTM)79.93x

Revenue Growth QoQ (YoY)10.16%

EPS Growth (5Y)-2.88%

P/E Normalized (Annual)119.35x

ROA (Last FY)3.15%

Revenue Growth TTM (YoY)10.39%

EBITD / Share (TTM)$9.95

ROE (5Y Avg)70.88%

Operating Margin (TTM)26.20%

Cash Flow / Share (Annual)$10.08

P/B Ratio355.19x

P/B Ratio (Quarterly)261.01x

Net Income / Employee (Annual)$74,100

EV / Revenue (TTM)8.83x

Net Interest Coverage (TTM)3.46x

ROA (TTM)4.68%

EPS Growth QoQ (YoY)285.22%

EV / EBITDA (TTM)32.22x

EPS Incl Extra (Annual)$2.38

Current Ratio (Annual)0.67x

Quick Ratio (Quarterly)0.49x

3-Month Avg Trading Volume5.92M

52-Week Price Return25.81%

EV / Free Cash Flow (Annual)31.92x

P/E Incl Extra (TTM)79.93x

Revenue / Employee (TTM)$1,129,600

Tangible BV / Share (Quarterly)$0.14

P/S Ratio (Annual)8.25x

Asset Turnover (Annual)0.46x

52-Week High$291.40

Operating Margin (5Y Avg)25.49%

EPS Excl Extra (Annual)$2.38

CapEx CAGR (5Y)8.75%

26-Week Price Return35.75%

Quick Ratio (Annual)0.41x

13-Week Price Return12.15%

Total Debt / Equity (Annual)20.19x

Current Ratio (Quarterly)0.81x

Enterprise Value$568.62B

Revenue / Share Growth (5Y)4.73%

Asset Turnover (TTM)0.48x

Book Value / Share Growth (5Y)-10.06%

Revenue / Employee (Annual)$1,073,000

Inventory Turnover (Annual)3.80x

Pretax Margin (Annual)10.79%

Cash / Share (Annual)$2.97

3-Month Return Std Dev21.21%

Gross Margin (5Y Avg)69.76%

Net Income / Employee (TTM)$110,700

EBITDA CAGR (5Y)5.65%

EBITDA Interim CAGR (5Y)7.38%

ROE (Last FY)128.66%

Net Interest Coverage (Annual)4.25x

EPS Basic Excl Extra (Annual)$2.38

P/FCF (TTM)27.70x

Receivables Turnover (TTM)4.87x

EV / Free Cash Flow (TTM)31.23x

Total Debt / Equity (Quarterly)49.22x

EPS Incl Extra (TTM)$3.56

Receivables Turnover (Annual)5.20x

ROI (TTM)5.66%

Dividend Growth Rate (5Y)6.76%

P/S Ratio (TTM)7.83x

Pretax Margin (5Y Avg)15.04%

Revenue / Share (Annual)$34.50

Tangible BV / Share (Annual)$0.14

Forward P/E16.93x

Free OCF CAGR (5Y)1.19%

Price vs S&P 500 (52W)10.28%

P/E Ratio (TTM)79.93x

EPS Growth TTM (YoY)67.60%

Year-to-Date Return24.92%

5-Day Price Return1.53%

EPS Normalized (Annual)$2.38

ROA (5Y Avg)5.27%

Net Profit Margin (Annual)6.91%

Month-to-Date Return9.11%

Cash Flow / Share (TTM)$8.66

EBITD / Share (Annual)$8.93

EPS Growth (3Y)-28.99%

Operating Margin (Annual)24.65%

LT Debt / Equity (Annual)18.14x

P/CF (TTM)25.86x

ROI (5Y Avg)8.99%

P/E Excl Extra (TTM)79.93x

LT Debt / Equity (Quarterly)45.44x

EPS Basic Excl Extra (TTM)$3.56

P/TBV (Quarterly)455.35x

Payout Ratio (Annual)275.84%

P/B Ratio (Annual)94.44x

Dividend / Share (TTM)$6.78

Inventory Turnover (TTM)3.47x

Pretax Margin (TTM)13.51%

Book Value / Share (Annual)$1.88

Price vs S&P 500 (13W)9.47%

Net Margin Growth (5Y)-7.27%

Dividend Yield (TTM)2.37%

Beta0.19x

P/FCF (Annual)28.31x

Revenue / Share (TTM)$36.36

ROE (TTM)95.59%

52-Week Low$190.75

vGradeD

gGradeC

mGradeA

vgmGradeC

ABBV Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 31, 2026	$3.61	$3.65	+1.15%(+$0.04)
Q1 2026	Apr 29, 2026	$2.67	$2.65	-0.77%(-$0.02)
Q4 2025	Feb 4, 2026	$2.65	$2.71	+2.16%(+$0.06)
Q3 2025	Oct 31, 2025	$1.78	$1.86	+4.23%(+$0.08)
Q2 2025	Jul 31, 2025	$2.91	$2.97	+2.14%(+$0.06)

ABBV Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

4.03

4.05

4.08

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About ABBVIE INC.

AbbVie is a diversified pharmaceutical company with core franchises in immunology (Humira, Skyrizi, Rinvoq) and oncology (Imbruvica, Venclexta), complemented by a growing aesthetics business anchored by Botox following the 2020 Allergan acquisition. Recent 2024 acquisitions of Cerevel Therapeutics and Immunogen strengthen its neuroscience and oncology pipelines. The company's multi-therapeutic portfolio leverages established market positions and provides diversified revenue streams.